| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.25 | 8e-12 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-11 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-08 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.23 | 6e-06 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |